The forward osmosis (FO) process is an emerging technology that has been considered as an alternative to desalination due to its low energy consumption and less severe reversible fouling. Artificial neural networks (ANNs) and response surface methodology (RSM) have become popular for the modeling and optimization of membrane processes. RSM requires the data on a specific experimental design whereas ANN does not. In this work, a combined ANN-RSM approach is presented to predict and optimize the membrane flux for the FO process. The ANN model, developed based on an experimental study, is used to predict the membrane flux for the experimental design in order to create the RSM model for optimization. A Box-Behnken design (BBD) is used to develop a response surface design where the ANN model evaluates the responses. The input variables were osmotic pressure difference, feed solution (FS) velocity, draw solution (DS) velocity, FS temperature, and DS temperature. The R2 obtained for the developed ANN and RSM model are 0.98036 and 0.9408, respectively. The weights of the ANN model and the response surface plots were used to optimize and study the influence of the operating conditions on the membrane flux.Plastic waste reduction and recycling through circular use has been critical nowadays, since there is an increasing demand for the production of plastic components based on different polymeric matrices in various applications. The most commonly used recycling procedure, especially for thermoplastic materials, is based on thermomechanical process protocols that could significantly alter the polymers' macromolecular structure and physicochemical properties. The study at hand focuses on recycling of polyamide 12 (PA12) filament, through extrusion melting over multiple recycling courses, giving insight for its effect on the mechanical and thermal properties of Fused Filament Fabrication (FFF) manufactured specimens throughout the recycling courses. Three-dimensional (3D) FFF printed specimens were produced from virgin as well as recycled PA12 filament, while they have been experimentally tested further for their tensile, flexural, impact and micro-hardness mechanical properties. A thorough thermal and morphological analysis was also performed on all the 3D printed samples. The results of this study demonstrate that PA12 can be successfully recycled for a certain number of courses and could be utilized in 3D printing, while exhibiting improved mechanical properties when compared to virgin material for a certain number of recycling repetitions. From this work, it can be deduced that PA12 can be a viable option for circular use and 3D printing, offering an overall positive impact on recycling, while realizing 3D printed components using recycled filaments with enhanced mechanical and thermal stability.Although stage I and II colon cancers (CC) generally show a very good prognosis, a small proportion of these patients dies from recurrent disease. The identification of high-risk patients, who may benefit from adjuvant chemotherapy, becomes therefore essential. We retrospectively evaluated 107 cases of stage I (n = 28, 26.2%) and II (n = 79, 73.8%) CC for correlations among preoperative inflammatory markers, histopathological factors and long-term prognosis. A neutrophil-to-lymphocyte ratio greater than 3 (H-NLR) and a platelet-to-lymphocyte ratio greater than 150 (H-PLR) were significantly associated with the presence of poorly differentiated clusters (PDC) (p = 0.007 and p = 0.039, respectively). In addition, H-NLR and PDC proved to be significant and independent survival prognosticators for overall survival (OS; p = 0.007 and p less then 0.001, respectively), while PDC was the only significant prognostic factor for cancer-specific survival (CSS; p less then 0.001,). Finally, the combination of H-NLR and PDC allowed an optimal stratification of OS and CSS in our cohort, suggesting a potential role in clinical practice for the identification of high-risk patients with stage I and II CC.Stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells (ASCs) are able to repair/replace damaged or degenerative tissues and improve functional recovery in experimental model and clinical trials. However, there are still many limitations and unresolved problems regarding stem cell therapy in terms of ethical barriers, immune rejection, tumorigenicity, and cell sources. By reviewing recent literatures and our related works, human amnion-derived stem cells (hADSCs) including human amniotic mesenchymal stem cells (hAMSCs) and human amniotic epithelial stem cells (hAESCs) have shown considerable advantages over other stem cells. In this review, we first described the biological characteristics and advantages of hADSCs, especially for their high pluripotency and immunomodulatory effects. Then, we summarized the therapeutic applications and recent progresses of hADSCs in treating various diseases for preclinical research and clinical trials. In addition, the possible mechanisms and the challenges of hADSCs applications have been also discussed. Finally, we highlighted the properties of hADSCs as a promising source of stem cells for cell therapy and regenerative medicine and pointed out the perspectives for the directions of hADSCs applications clinically.Soft tissue and bone sarcomas are a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. On top of that, the treatment choices are limited, and the prognosis of aggressive sarcomas remains poor. https://www.selleckchem.com/products/Roscovitine.html Immune checkpoint inhibitors (ICIs) have drawn a lot of attention last years because of their promising response rates and their durable effects. ICIs are currently widely used in the daily routine practice for the treatment of a different malignancies, such as melanoma, Hodgkin lymphoma, and non-small cell lung carcinoma. Still, ICIs are not included in the standard treatment protocols of the different sarcoma types. However, a plethora of clinical trials investigates the clinical benefit of ICIs in sarcomas. There is clear need to develop predictive biomarkers to determine which sarcoma patients are most likely to benefit from immune checkpoint blockade. This review will focus on (i) the clinical trial results on the use of ICIs in different sarcoma types; and on (ii) possible biomarkers predictive for the effectiveness of these drugs in sarcomas.